Taffic Tablets Clincial Trials Data for Healthcare Professionals |IV AIDS symptoms, HIV AIDS treatme

Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets (Taffic) – Overview for Healthcare Professionals

Taffic is a fixed-dose combination antiretroviral tablet containing bictegravir, emtricitabine, and tenofovir alafenamide (TAF), indicated for the treatment of HIV-1 infection in adults and adolescents meeting approved criteria. Bictegravir is an integrase strand transfer inhibitor (INSTI) that prevents integration of viral DNA into the host genome, while emtricitabine and TAF are nucleos(t)ide reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcription. This triple-mechanism approach provides potent viral suppression and a high barrier to resistance.

Taffic is typically prescribed as one tablet once daily, with or without food, improving adherence compared with multi-pill regimens. It is used both in treatment-naïve patients and in virologically suppressed patients switching therapy, provided there is no known resistance to its components. Clinical studies have shown sustained viral load suppression and increases in CD4 cell counts.

Common adverse reactions may include headache, nausea, diarrhea, and fatigue; serious effects such as renal impairment, hepatic issues, or lactic acidosis are uncommon but require monitoring. TAF is associated with improved renal and bone safety compared with older tenofovir formulations.

Overall, Taffic represents a well-tolerated, guideline-recommended option in modern HIV/AIDS treatment strategies, supporting long-term disease control and improved quality of life.